Incannex Stock Trading Higher On Entering A Lease For First Psychedelic-Assisted Psychotherapy Clinic
Incannex Healthcare Ltd (NASDAQ: IXHL) (ASX:IHL) announced that its subsidiary company, Clarion Clinics Group Pty Ltd, has entered a lease for riverfront premises in Abbottsford, Melbourne.
The premises will be used to provide psychedelic-assisted psychotherapy. Fit out and commissioning of these premises is due to commence shortly and is expected to be complete in August 2023, facilitating the opening of the first clinic shortly thereafter.
The clinic is designed as a commercial scale prototype, which can be scaled up and replicated to other locations. It will have capacity to treat over 600 patients per year in normal working hours and substantially more in extended hour operations.
Incannex has ordered an initial supply of psilocybin and MDMA, through an arrangement with Pharmala Biotech, to facilitate the commencement of clinical operations.
Incannex CEO and managing director, Joel Latham stated: “Clarion Clinics will be the first dedicated psychedelic-assisted psychotherapy business in Australia. We’re delighted to be at the forefront of an industry that has the potential to change the lives of thousands of people who have been living with conditions for which there have been no adequate treatment options.”
Price Action
Incannex shares were trading 7.91% higher at $1.91 during Friday's pre-market session.
Photo: Benzinga edit with photos by geralt and sergeitokmakov on Pixabay
Related News
New Clinical MDMA And Psilocybin Batches Head To Flourishing Psychedelics Market
Incannex Healthcare Prepares To Launch Psychedelics Clinics Via New Subsidiary
Psychedelic Trials Update: Treating Meth Addiction, Fibromyalgia & General Anxiety Disorder
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Clarion Clinics Group Joel Latham premiumCannabis News Penny Stocks Psychedelics Markets